Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 4/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2017807 | 0.83 | ESR1 (0.43) | NPSR1SMN1; SMN2ESR1ESR2CA1 | |
| SCHEMBL1996287 | 0.81 | ESR1 (0.55) | NPSR1CYP3A4CYP2C19CYP2C9SMN1; SMN2 | |
| SCHEMBL31237497 | 0.81 | NPSR1 (0.57) | NPSR1CYP3A4CYP2C19CYP2C9SMN1; SMN2 | |
| SCHEMBL20707998 | 0.76 | HIF1A (0.45) | NPSR1CYP3A4CYP2C19CYP2C9SMN1; SMN2 | |
| SCHEMBL1997707 | 0.75 | HTR7 (0.42) | NPSR1ESR1ESR2ALDH1A1 | |
| SCHEMBL20695904 | 0.75 | HTR7 (0.37) | CYP3A4SMN1; SMN2ESR1ESR2 | |
| SCHEMBL19423013 | 0.75 | HTR7 (0.37) | CYP3A4SMN1; SMN2ESR1ESR2 | |
| SCHEMBL22773172 | 0.75 | HTR7 (0.37) | CYP3A4SMN1; SMN2ESR1ESR2 | |
| SCHEMBL30479084 | 0.75 | HTR7 (0.37) | CYP3A4SMN1; SMN2ESR1ESR2 | |
| SCHEMBL11832035 | 0.71 | SMN1; SMN2 (0.59) | NPSR1CYP3A4CYP2C19CYP2C9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309734-A1 | COMBRETASTATIN DERIVATIVES AND USES THEREFOR | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2012-12-06 | — | — | US | disclosed |
| EP-2338877-A1 | Combretastatin Derivatives and Uses Therefor | The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin (IE) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309734-A1 | COMBRETASTATIN DERIVATIVES AND USES THEREFOR | CASP4, CA4, ACSL4 | NPSR1 4345/4885CYP3A4 264/4885CYP2C19 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.